Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR | Market Cap | 609.98M |
| Revenue (ttm) | 14.09M |
| Net Income (ttm) | -184.21M |
| Shares Out | 139.11M |
| EPS (ttm) | -3.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,131 |
| Average Volume | 300,580 |
| Open | 4.380 |
| Previous Close | 4.410 |
| Day's Range | 4.240 - 4.490 |
| 52-Week Range | 1.430 - 5.260 |
| Beta | 0.74 |
| RSI | 54.05 |
| Earnings Date | Sep 26, 2025 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th... [Read more]
Financial Performance
In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.
Financial StatementsNews
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. ...
Today's Analyst Rating: Inventiva (IVA) Receives 'Buy' Rating from HC Wainwright & Co. | IVA Stock News
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Guggenhei...
Inventiva surges as Piper Sandler issues bullish view citing lead asset
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the ...
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva receives $10 million milestone payment from CTTQ
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Inventiva S.A. reports Q1 results
Inventiva reports 2025 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development...
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development...
Inventiva secures €116 million second tranche of structured financing of up to €348 million
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t...
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Inventiva reports its 2024 full year results and provides a business update
Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developme...
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused o...
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focuse...
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutica...